DNA2.0 Expands European Presence by Opening UK Office
News Dec 11, 2008
DNA2.0 has announced the expansion of the company’s European operations with the creation of the United Kingdom-based DNA2.0 Ltd.
Michael Dyson, PhD, has been appointed as Managing Director of European Operations and will lead the new venture in the UK as well as DNA2.0’s established office in Basel, Switzerland.
“The opening of our UK headquarters represents a major step in our global growth,” said Jeremy Minshull, President of DNA2.0. “Even in a time of economic uncertainty, the market for gene synthesis and its many applications continues to grow rapidly in Europe. We are confident that European customers will continue to seek out our world-class customer support, fast and reliable turnaround time and the certainty that their intellectual property is completely protected.”
The Company says that, while many other gene synthesis companies offshore manufacturing to areas of the world with lax IP protection, all DNA2.0 genes are made at the company’s facility in Menlo Park, thus ensuring the greatest security for patented or confidential sequences. DNA2.0’s two European locations ensure that European customers receive the same PhD-level service and support as their US counterparts.
“The demand in the European marketplace for high quality synthetic genes, delivered quickly and with confidence, is tremendous,” said Dr. Dyson. “We look forward to serving our European customers even more effectively through this new base of operations.”
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE